Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-04-28

Clinical Trial Update: Study Utilizing Rilonacept in Gout Exacerbations [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating rilonacept for acute gout flares has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Rilonacept (Arcalyst) (rilonacept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Acute Gout Flare | Phase 3 | Status: COMPLETED | Results posted: 2017-04-28